XOMA Royalty Expands Its Milestone Portfolio Significantly
XOMA Royalty has made a strategic move by acquiring a significant stake in Twist Bioscience's promising early-stage programs, enhancing its diverse portfolio and financial outlook.
Details of the Acquisition
Through a recent transaction, XOMA Royalty Corporation (NASDAQ: XOMA) invested $15 million to secure a 50 percent interest in the royalties and milestones associated with over 60 innovative partnered programs involving 30 different partners in the biotech field.
The Value of this Partnership
Brad Sitko, the Chief Investment Officer at XOMA Royalty, expressed that this acquisition strengthens their unique position within the biotech royalty sector. He emphasized how a growing base of commercial revenues and an extensive early pipeline can deliver superior risk-adjusted returns for their stakeholders.
Understanding Biopharma Solutions with Twist Bioscience
This partnership derives from Twist Bioscience’s Biopharma Solutions unit, which provides a platform for these early-stage innovations. This arrangement will not only diversify XOMA Royalty’s portfolio but is expected to contribute positively to its earnings.
What This Means for Investors
With this strategic acquisition, XOMA Royalty is poised to enhance its revenue stream significantly. The company now boasts a portfolio that exceeds 100 assets, tapping into various therapeutic areas from established commercial products to pre-clinical candidates. This breadth is fundamental for investors seeking growth through innovation in the biotech sector.
The Role of XOMA Royalty
XOMA Royalty Corporation operates as a biotechnology royalty aggregator, playing a pivotal role in fostering advancements in healthcare. By acquiring potential future earnings related to pre-commercial therapeutic candidates, they provide essential non-dilutive funding to biotech companies, enabling them to further develop their internal drug candidates.
Portfolio Highlights
As it stands, XOMA Royalty’s diverse portfolio now includes a blend of commercial therapeutic products alongside investigational compounds. Current commercial assets feature various products like VABYSMO (faricimab-svoa), OJEMDA (tovorafenib), and DSUVIA (sufentanil sublingual tablet), among others. Each product represents an opportunity for revenue generation as the healthcare landscape continues to evolve.
Investor Relations and Media Contacts
The XOMA Royalty investment team is led by Juliane Snowden, who is available for inquiries at +1 646-438-9754 or via email at juliane.snowden@xoma.com. For media-related questions, Kathy Vincent can be reached at +1 310-403-8951 or kathy@kathyvincent.com.
Frequently Asked Questions
What is the significance of the XOMA and Twist Bioscience partnership?
The partnership enhances XOMA's portfolio by integrating over 60 early-stage programs, leading to greater revenue opportunities and shareholder value.
How much did XOMA invest in the acquisition?
XOMA Royalty invested $15 million for a 50 percent stake in the royalties and milestones related to the partnered programs at Twist Bioscience.
What types of assets are included in XOMA's portfolio?
XOMA's portfolio includes a mix of revenue-generating commercial therapeutics and early-stage investigational programs across various therapeutic areas.
Who leads the investor relations for XOMA?
Juliane Snowden is the primary contact for investor relations, helping stakeholders with inquiries about the company's activities and growth potential.
How does XOMA support biotech companies?
XOMA provides non-dilutive funding to biotech firms by acquiring future economics tied to their therapeutic candidates, aiding their development and market positioning.
